Clinical Trials Browser

Biliary Tract Neoplasms

NCT06739252 2026-01-28

Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA

Phase 2 Terminated

1 enrolled

Gastrointestinal

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma, Klatskin Tumor

NCT04425070 2026-01-05

TOUCH

Phase 1/2 Terminated

56 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

NCT03478488 2025-05-29

KN035-BTC

Phase 3 Active not recruiting

480 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT06505486 2024-07-17

GEMOX-HAIC Plus GEM-SYS in Combination With Lenvatinib and PD-1 Inhibitor for Large Unresectable ICC

Recruiting

21 enrolled

Gastrointestinal

Cholangiocarcinoma

NCT06320301 2024-03-20

Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC)

Phase 2 Recruiting

43 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT01726582 2023-08-14

Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")

Phase 2 Completed

229 enrolled 14 charts

Gastrointestinal

Adenocarcinoma, Neoplasms, Pancreatic Neoplasms

NCT05036798 2022-09-07

Tislelizumab+Lenvatinib+Gemox Regiment for Potentially Resectable Locally Advanced Malignant Tumors of Biliary System.

Phase 2 Unknown

30 enrolled

Gastrointestinal

Potentially Resectable Locally Advanced Malignant Tumors of Biliary System

NCT05517239 2022-08-26

PEACH

Phase 2 Completed

32 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT04948788 2021-09-28

SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma

Phase 2 Unknown

102 enrolled

Lymphoid

Recurrence, Lymphoma, B-Cell

NCT01267344 2016-05-04

BTC

Phase 2 Completed

122 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT00169195 2015-09-02

Rituximab, Gemcitabine and Oxaliplatin (R-GEMOX) for Refractory/Relapsed B-cell Lymphoma

Phase 2 Completed

49 enrolled

Lymphoid

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00127595 2005-08-24

Oxaliplatin With Gemcitabine in Patients With Carcinoma of the Urothelial Tract

Phase 2 Terminated

28 enrolled

Genitourinary

Carcinoma, Transitional Cell

Clinical Trials

TOURMALINE

Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA

TOUCH

KN035-BTC

GEMOX-HAIC Plus GEM-SYS in Combination With Lenvatinib and PD-1 Inhibitor for Large Unresectable ICC

Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC)

Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")

Tislelizumab+Lenvatinib+Gemox Regiment for Potentially Resectable Locally Advanced Malignant Tumors of Biliary System.

PEACH

SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma

BTC

Rituximab, Gemcitabine and Oxaliplatin (R-GEMOX) for Refractory/Relapsed B-cell Lymphoma

Oxaliplatin With Gemcitabine in Patients With Carcinoma of the Urothelial Tract